Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and infectious diseases on people’s lives is why we’re here

Innovation and research

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

A vaccine platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ vaccine has the potential to treat many disease areas, including cancer.

Highlights

H.C. Wainwright 24th Annual Global Investment Conference, September 13, 2022 ...

Read More
13 September 2022

Nykode Therapeutics to present at H.C. Wainwright 24th Annual ...

Read More
12 September 2022

Nykode Therapeutics to be included in the Oslo Børs ...

Read More
08 September 2022

1H 2022 FINANCIAL RESULTS – presentation

Read More
24 August 2022

Nykode Therapeutics to announce financial results for the first ...

Read More
22 August 2022

Nykode Therapeutics uplisted to the main list of the ...

Read More
16 June 2022

Nykode Therapeutics – approval and publication of prospectus and ...

Read More
15 June 2022

Nykode Therapeutics appoints Klaus Edvardsen as Chief Development Officer

Read More
13 June 2022

Jefferies Healthcare Conference, June 8-10, 2022 – presentation

Read More
08 June 2022